studies

1074A AASLD ABSTRACTS HEPATOLOGY, October, 2015
Disclosures:
William M. Lee - Consulting: Eli Lilly, Sanofi; Grant/Research Support: Gilead,
BMS, Vertex, Merck
The following authors have nothing to disclose: Jody A. Rule, Linda S. Hynan,
Nahid Attar, William J. Korzun
Disclosures:
William Bernal - Advisory Committees or Review Panels: Ocera Therapeutics ;
Consulting: Vital Therapies Inc
Julia Wendon - Consulting: Pulsion, Excalenz
The following authors have nothing to disclose: Georg Auzinger, Robert Loveridge,
Sameer Patel, Christopher Willars, Krishna Menon, Hector Vilca-Melendez
1776
Serial Procalcitonin Measurements in Acute Liver Failure
Patients with Bacterial Infections
Jody A. Rule 1 , Linda S. Hynan 1 , Nahid Attar 1 , William J. Korzun
2 , William M. Lee 1 ; 1 Internal Medicine, University of Texas
Southwestern Medical Center, Dallas, TX; 2 Allied Health, Virginia
Commonwealth University, Richmond, VA
Background: Multi-organ failure in ALF patients resembles
severe sepsis and septic shock, making identification of bacterial
infection can be difficult. Procalcitonin (PCT) has proven
useful in sepsis in general to identify and predict response
to infection. We hypothesized that serial PCT values in ALF
patients might be predictive of outcome. Methods: Among ALF
Study Group 47 patients with bacterial infection (positive culture
on Day 1), we compared serial PCT levels in sera available
at least for Days 1-4, using the ADVIA Centaur BRAHMS PCT
assay, a sandwich chemi-luminescent immunoassay, comparing
change in levels to outcome as spontaneous survival (SS)
vs. death/transplantation (non-SS). Results: Elevated PCT levels
were observed in all patients (median 2.31 ng/mL), falling rapidly
in the SS group from median of 2.9 to 1.07 ng/mL by Day
4, compared to the non-SS group that actually increased from
1.42 to 2.04 ng/mL by Day 4. Both groups had an overall
decrease by Day 7 of 70.3% (SS) and 49.3% (non-SS). Conclusions:
High PCT levels are characteristic of most ALF subjects
falling to